Clinical study · LORIO DTx
Keeping the benefits of pulmonary rehabilitation, every day, at home
HAPPLYZ Medical is preparing a multicentre clinical study to evaluate LORIO DTx, its digital therapy for people living with COPD after a pulmonary rehabilitation programme.
- 6pulmonary rehabilitation centres
- COPDafter pulmonary rehabilitation
- 2027launch

Why this study?
Pulmonary rehabilitation clearly improves breathing, endurance and quality of life for people with COPD. Once the programme ends, however, these benefits often fade within a few months, because exercising over the long term is hard.
Exacerbations, sudden flare-ups of symptoms, remain one of the major challenges of the disease: they cause lasting damage to lung function and often lead to hospital.
LORIO DTx in a nutshell
- A daily breathing exercise programme, done at home with the LORIO connected flute and a tablet.
- Exercises designed as games, so that each session becomes an enjoyable routine.
- A programme that adapts to how the patient feels: a gentler version is offered on harder days.
- Follow-up by the care team (pulmonologist, physiotherapist).
Who can take part?
The study is aimed at people with COPD completing a pulmonary rehabilitation programme in one of the participating centres.
Participation is offered by the centre's medical team, after the patient has been informed and has given consent. There is no online registration.
A study led with respiratory experts
The study brings together some of France's leading pulmonologists, across six pulmonary rehabilitation centres.
It is supported by the Caisse des Dépôts – Banque des Territoires as part of France 2030, by the ERDF (European Union), and by the IN CITU experimentation hub.
LORIO DTx is a medical device under clinical evaluation and is not yet available. The LORIO products currently on sale (LORIO Pro, LORIO at home) are separate devices, CE marked as class I.
Healthcare professional? Contact us Follow our progress on the blog

